Nigel H. Russell

24.3k total citations · 3 hit papers
355 papers, 12.4k citations indexed

About

Nigel H. Russell is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Nigel H. Russell has authored 355 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 293 papers in Hematology, 106 papers in Molecular Biology and 106 papers in Oncology. Recurrent topics in Nigel H. Russell's work include Acute Myeloid Leukemia Research (196 papers), Hematopoietic Stem Cell Transplantation (97 papers) and Acute Lymphoblastic Leukemia research (78 papers). Nigel H. Russell is often cited by papers focused on Acute Myeloid Leukemia Research (196 papers), Hematopoietic Stem Cell Transplantation (97 papers) and Acute Lymphoblastic Leukemia research (78 papers). Nigel H. Russell collaborates with scholars based in United Kingdom, United States and Denmark. Nigel H. Russell's co-authors include Robert K. Hills, Alan K. Burnett, Monica Pallis, Claire Seedhouse, Donald Milligan, Richard F. Schlenk, Mark J. Levis, Keith Wheatley, Naval Daver and Emma Das‐Gupta and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Nigel H. Russell

348 papers receiving 12.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting FLT3 mutations in AML: review of current knowledge and evidence

2019 674 citations Nigel H. Russell, Mark J. Levis et al. profile →
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

2010 490 citations Alan K. Burnett, Robert K. Hills et al. Journal of Clinical Oncology profile →
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

2015 346 citations Alan K. Burnett, Nigel H. Russell et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Nigel H. Russell

Since Specialization

Citations

This map shows the geographic impact of Nigel H. Russell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel H. Russell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel H. Russell more than expected).

Fields of papers citing papers by Nigel H. Russell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel H. Russell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel H. Russell. The network helps show where Nigel H. Russell may publish in the future.

Co-authorship network of co-authors of Nigel H. Russell

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel H. Russell. A scholar is included among the top collaborators of Nigel H. Russell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel H. Russell. Nigel H. Russell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML 2025 ·Blood Advances ·Nigel H. Russell, Jad Othman, Oliver Cumming, Abin Thomas, (unknown), Nicola Potter, Jelena Jovanović, Amanda Gilkes, (unknown), Joanna Canham, (unknown), Manohursingh Runglall, (unknown), Panagiotis Kottaridis, James D. Cavenagh, (unknown), Sylvie Freeman, Mike Dennis, Steven Knapper, Richard Dillon	0
2	Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission 2024 ·Blood ·Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanović, Manohursingh Runglall, Sylvie Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, (unknown), Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan K. Burnett, Charlotte S. Wilhelm-Benartzi, Richard Dillon, Nigel H. Russell	33
3	Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia 2024 ·Blood ·Sun Loo, Nicola Potter, Adam Ivey, Jenny O’Nions, R C Moon, Jelena Jovanović, Chun Yew Fong, Natasha S. Anstee, Ing Soo Tiong, Jad Othman, Chong Chyn Chua, (unknown), (unknown), Shaun Fleming, Nigel H. Russell, David Ritchie, Ashish Bajel, Hsin‐An Hou, Richard Dillon, Andrew H. Wei	4
4	Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome 2022 ·Blood ·Sun Loo, Richard Dillon, Adam Ivey, Natasha S. Anstee, Jad Othman, Ing Soo Tiong, Nicola Potter, Jelena Jovanović, Manohursingh Runglall, (unknown), Ashish Bajel, David Ritchie, (unknown), (unknown), Michelle McBean, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei	42
5	A randomised evaluation of low‐dose Ara‐C plus pegylated recombinant arginase BCT‐100 versus low dose Ara‐C in older unfit patients with acute myeloid leukaemia: Results from the LI‐1 trial 2022 ·British Journal of Haematology ·Francis Mussai, Carmela De Santo, Paul Cheng, Ian F. Thomas, Cono Ariti, (unknown), (unknown), (unknown), (unknown), Alan K. Burnett, Steven Knapper, Priyanka Mehta, Mary Frances McMullin, Mhairi Copland, Nigel H. Russell, Mike Dennis	7
6	Therapy for isocitrate dehydrogenase 2 (IDH2)^R172‐mutant acute myeloid leukaemia 2021 ·British Journal of Haematology ·David C. Linch, Robert K. Hills, Alan K. Burnett, Nigel H. Russell, Rosemary E. Gale	2
7	Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases 2020 ·Blood Advances ·Giancarlo Fatobene, Fernanda Volt, Frederico Rafael Moreira, (unknown), Patrice Chevallier, Sabine Fürst, Hélène Labussière‐Wallet, Régis Peffault de la Tour, Éric Deconinck, Thomas Cluzeau, Nigel H. Russell, Dimitrios Karakasis, Édouard Forcade, Annalisa Ruggeri, Éliane Gluckman, Vanderson Rocha	7
8	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses 2020 ·Journal of Clinical Oncology ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Steven Knapper, Sylvie Freeman, Brian J.P. Huntly, Richard E. Clark, Ian F. Thomas, Lars Kjeldsen, Mary Frances McMullin, Mark W. Drummond, Jonathan Kell, Ruth Spearing	19
9	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia 2019 ·Blood Advances ·Paul Milne, Charlotte S. Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie Freeman, Kathleen Gallagher, (unknown), Sarah Pagan, Helen Marr, Gail Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark J. Levis, Steven Knapper, Matthew Collin	17
10	Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies 2019 ·Blood ·Daniel Sasca, Haiyang Yun, George Giotopoulos, (unknown), Theodore Evan, Nicola K. Wilson, Moritz Gerstung, Paolo Gallipoli, (unknown), Robert K. Hills, Nigel H. Russell, Cameron S. Osborne, Elli Papaemmanuil, Berthold Göttgens, Peter J. Campbell, Brian J.P. Huntly	39
11	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, David Bowen, Jonathan Kell, Steven Knapper, Yvonne G Morgan, (unknown), Angela Grech, Gail Jones, Asim Khwaja, Lone S. Friis, Mary Frances McMullin, Ann Hunter, Richard E. Clark, David Grimwade	346
12	Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial 2013 ·Journal of Clinical Oncology ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Ann E. Hunter, Lars Kjeldsen, John Liu Yin, Brenda Gibson, Keith Wheatley, Donald Milligan	289
13	Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia 2011 ·Blood ·Judith Marsh, Vikas Gupta, ZiYi Lim, Aloysius Ho, Robin Ireland, Janet Hayden, Victoria Potter, Mickey Koh, (unknown), Nigel H. Russell, David I. Marks, Ghulam J. Mufti, Antonio Pagliuca	105
14	The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells 2010 ·Molecular Cancer Therapeutics ·Martin Grundy, Claire Seedhouse, (unknown), (unknown), Nigel H. Russell, Monica Pallis	32
15	Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials 2007 ·Clinical Cancer Research ·Claire Seedhouse, Martin Grundy, P. Bruce White, Yun Li, Janet Fisher, (unknown), Anthony V. Moorman, T. G. Hoy, Nigel H. Russell, Alan K. Burnett, Monica Pallis	34
16	Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial 2003 ·Blood ·Alan K. Burnett, Robert K. Hills, A H Goldstone, A. G. Prentice, Don Milligan, Monica Pallis, Nigel H. Russell, (unknown), Keith Wheatley	4
17	Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced‐intensity conditioning compared with standard preparative regimens 2002 ·British Journal of Haematology ·Jane E. Parker, Tariq Shafi, Antonio Pagliuca, Aleksandar Mijović, Stephen Devereux, Mike Potter, H. G. Prentice, Mamta Garg, John A. Liu Yin, Jenny Byrne, Nigel H. Russell, Ghulam J. Mufti	66
18	Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation 2001 ·Bone Marrow Transplantation ·Per Ljungman, (unknown), Bruce Crooks, Anne Parker, Rodrigo Martino, Peter J. Shaw, Lorentz Brinch, Mats Brune, Rafael de la Cámara, Andrew Dekker, Karlis Pauksen, Nigel H. Russell, (unknown), Catherine Cordonnier	226
19	A Comparison of Two Different Systems for CD34+ Selection of Autologous or Allogeneic PBSC Collections 1998 ·Journal of Hematotherapy ·C Stainer, Gail Miflin, Stacy Anderson, (unknown), I. Grant McQuaker, Nigel H. Russell	22
20	Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients 1994 ·British Journal of Haematology ·Jennifer M. Bird, (unknown), Diana Samson, Robert Marcus, Nigel H. Russell, Stephen M. Kelsey, A. C. Newland, Jane F. Apperley	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact